Comprehensive Stock Comparison
Compare BiomX Inc. (PHGE) vs argenx SE (ARGX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety |  ARGX | Beta 0.44 vs PHGE's 0.93, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ARGX | +17.8% vs PHGE's -48.8% |
| Efficiency (ROA) | ARGX | 12.9% ROA vs PHGE's -142.8%, ROIC -0.5% vs -305.2% |
Who Each Stock Is For
Income & stability
ARGXbeta 0.44
Growth exposure
ARGXRev growth 78.6%, EPS growth 347.7%, 3Y rev CAGR 63.9%
Long-term compounding (10Y)
ARGX31.6% 10Y total return vs PHGE's -99.7%
Sleep-well-at-night portfolio
ARGXLower volatility, beta 0.44, Low D/E 0.7%, current ratio 7.29x
Defensive / Recession hedge
ARGXBeta 0.44, current ratio 7.29x
Business Model
What each company does and how it makes money
BiomX is a clinical-stage biotechnology company developing targeted phage therapies — viruses that kill specific harmful bacteria — for chronic diseases and skin conditions. It generates no commercial revenue yet but is funded through equity offerings and partnerships to advance its pipeline, which includes therapies for cystic fibrosis, inflammatory bowel diseases, and atopic dermatitis. The company's key advantage is its proprietary platform for discovering and engineering natural phages that precisely target disease-causing bacteria while sparing beneficial microbes.
argenx is a biotechnology company that develops antibody-based therapies for autoimmune diseases. It generates nearly all its revenue from VYVGART — its FcRn blocker for conditions like myasthenia gravis — with additional income from partnerships and licensing. The company's key advantage is its proprietary antibody engineering platform that creates differentiated therapies with potentially better safety and efficacy profiles.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ARGX 4
PHGE 0ARGX1/1 metricsARGX7/8 metricsARGX5/6 metricsARGX2/2 metricsARGX leads in 4 of 6 categories — strongest in Financial Metrics and Profitability & Efficiency. 1 category is tied.
Financial Metrics (TTM)
ARGX and PHGE operate at a comparable scale, with $4.0B and $0 in trailing revenue.
| Metric | PHGEBiomX Inc. | ARGXargenx SE |
|---|---|---|
| RevenueTrailing 12 months | $0 | $4.0B |
| EBITDAEarnings before interest/tax | -$6M | $95M |
| Net IncomeAfter-tax profit | -$37M | $923M |
| Free Cash FlowCash after capex | -$28M | $213M |
| Gross MarginGross profit ÷ Revenue | — | +75.5% |
| Operating MarginEBIT ÷ Revenue | — | -1.0% |
| Net MarginNet income ÷ Revenue | — | +23.3% |
| FCF MarginFCF ÷ Revenue | — | +5.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +5.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -6.5% | +12.6% |
Valuation Metrics
| Metric | PHGEBiomX Inc. | ARGXargenx SE |
|---|---|---|
| Market CapShares × price | $82.8B | $46.4B |
| Enterprise ValueMkt cap + debt − cash | $82.8B | $44.9B |
| Trailing P/EPrice ÷ TTM EPS | -4.29x | 58.65x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 24.99x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 21.18x |
| Price / BookPrice ÷ Book value/share | 3427.64x | 8.89x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
ARGX delivers a 15.1% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-4 for PHGE. ARGX carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to PHGE's 0.40x.
| Metric | PHGEBiomX Inc. | ARGXargenx SE |
|---|---|---|
| ROE (TTM)Return on equity | -3.6% | +15.1% |
| ROA (TTM)Return on assets | -142.8% | +12.9% |
| ROICReturn on invested capital | -3.1% | -0.5% |
| ROCEReturn on capital employed | -159.9% | -0.4% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | 0.40x | 0.01x |
| Net DebtTotal debt minus cash | -$8M | -$1.5B |
| Cash & Equiv.Liquid assets | $18M | $1.5B |
| Total DebtShort + long-term debt | $10M | $39M |
| Interest CoverageEBIT ÷ Interest expense | -36.86x | 166.64x |
Total Returns (with DRIP)
A $10,000 investment in ARGX five years ago would be worth $25,869 today (with dividends reinvested), compared to $47 for PHGE. Over the past 12 months, ARGX leads with a +17.8% total return vs PHGE's -48.8%. The 3-year compound annual growth rate (CAGR) favors ARGX at 29.9% vs PHGE's -59.1% — a key indicator of consistent wealth creation.
| Metric | PHGEBiomX Inc. | ARGXargenx SE |
|---|---|---|
| YTD ReturnYear-to-date | +194.4% | -10.8% |
| 1-Year ReturnPast 12 months | -48.8% | +17.8% |
| 3-Year ReturnCumulative with dividends | -93.2% | +119.3% |
| 5-Year ReturnCumulative with dividends | -99.5% | +158.7% |
| 10-Year ReturnCumulative with dividends | -99.7% | +3159.0% |
| CAGR (3Y)Annualised 3-year return | -59.1% | +29.9% |
Risk & Volatility
ARGX is the less volatile stock with a 0.44 beta — it tends to amplify market swings less than PHGE's 0.93 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ARGX currently trades 80.2% from its 52-week high vs PHGE's 42.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PHGEBiomX Inc. | ARGXargenx SE |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.93x | 0.44x |
| 52-Week HighHighest price in past year | $14.71 | $934.62 |
| 52-Week LowLowest price in past year | $1.56 | $510.06 |
| % of 52W HighCurrent price vs 52-week peak | +42.8% | +80.2% |
| RSI (14)Momentum oscillator 0–100 | 51.0 | 29.6 |
| Avg Volume (50D)Average daily shares traded | 1.3M | 358K |
Analyst Outlook
| Metric | PHGEBiomX Inc. | ARGXargenx SE |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $1026.71 |
| # AnalystsCovering analysts | — | 35 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Mar 26 | Change |
|---|---|---|---|
| BiomX Inc. (PHGE) | 100 | 0.23 | -99.8% |
| argenx SE (ARGX) | 100 | 493.29 | +393.3% |
argenx SE (ARGX) returned +159% over 5 years vs BiomX Inc. (PHGE)'s -100%. A $10,000 investment in ARGX 5 years ago would be worth $25,869 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| BiomX Inc. (PHGE) | $0.00 | $0.00 | — |
| argenx SE (ARGX) | $7M | $2.2B | +29130.4% |
argenx SE's revenue grew from $7M (2015) to $2.2B (2024) — a 87.9% CAGR.
Chart 3EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| BiomX Inc. (PHGE) | -3.27 | -1.47 | +55.0% |
| argenx SE (ARGX) | -1.06 | 12.78 | +1305.7% |
argenx SE's EPS grew from $-1.06 (2015) to $12.78 (2024).
Chart 4Free Cash Flow — 5 Years
BiomX Inc. generated $-37M FCF in 2024 (-18% vs 2021). argenx SE generated $-151M FCF in 2024 (+79% vs 2021).
PHGE vs ARGX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is PHGE or ARGX a better buy right now?
argenx SE (ARGX) offers the better valuation at 58.7x trailing P/E (25.0x forward), making it the more compelling value choice. Analysts rate argenx SE (ARGX) a "Buy" — based on 35 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — PHGE or ARGX?
Over the past 5 years, argenx SE (ARGX) delivered a total return of +158.7%, compared to -99.5% for BiomX Inc. (PHGE). A $10,000 investment in ARGX five years ago would be worth approximately $26K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ARGX returned +31.6% versus PHGE's -99.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — PHGE or ARGX?
By beta (market sensitivity over 5 years), argenx SE (ARGX) is the lower-risk stock at 0.44β versus BiomX Inc.'s 0.93β — meaning PHGE is approximately 111% more volatile than ARGX relative to the S&P 500. On balance sheet safety, argenx SE (ARGX) carries a lower debt/equity ratio of 1% versus 40% for BiomX Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — PHGE or ARGX?
argenx SE (ARGX) is the more profitable company, earning 38.0% net margin versus 0.0% for BiomX Inc. — meaning it keeps 38.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PHGE leads at 0.0% versus -1.0% for ARGX. At the gross margin level — before operating expenses — ARGX leads at 89.6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — PHGE or ARGX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is PHGE or ARGX better for a retirement portfolio?
For long-horizon retirement investors, argenx SE (ARGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.44)). Both have compounded well over 10 years (ARGX: +31.6%, PHGE: -99.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between PHGE and ARGX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.